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Introduction
Multiple Myeloma (MM) is characterized by the clonal proliferation of malignant plasma cells in the bone marrow. Bone destruction is a common manifestation of the disease and results from increased osteoclastic bone resorption and decreased bone formation. The development of lytic bone lesions occurs only in areas of bone adjacent to myeloma cells 1 suggesting that lytic lesions result from local overproduction of osteoclast stimulatory factors, which are secreted by MM cells, bone marrow stromal cell (BMSC), or both. One of these factors responsible for osteoclastic bone resorption might be MIP-1α, a low molecular weight chemokine that belongs to the RANTES family of chemokines and binds to receptors CCR1, CCR5 and CCR9. Recently, in vitro and in vivo studies have shown that MIP-1α is able to induce osteoclast (OCL) formation in marrow cultures 2 and is chemotactic for rat OCLs 3 .
Choi et al. have shown that MIP-1α is an OCL-stimulating factor in human marrow cultures
and is overexpressed in patients with MM, but not in healthy individuals 4 . Thus, blocking of MIP-1α using neutralizing antibodies inhibits the osteoclast stimulatory factor (OSF) activity in the bone marrow plasma from MM patients 4 . Furthermore inhibition of MIP-1α using antisense blocks bone destruction in SCID-mice 5 . These data suggest, that MIP-1α may play a major role in the microenvironment by mediating bone destruction in patients with MM.
So far, several cytokines from the bone marrow microenvironment have been implicated to contribute to the development of MM. Especially, interleukin 6 (IL-6) has been frequently suggested to be crucial for the pathogenesis of MM and has been shown to act as an autocrine, paracrine growth and survival factor [6] [7] [8] . However, treatment of MM patients with neutralizing
anti-IL-6 monoclonal antibody (mab) has only shown marginal effects 9, 10 , leading to the following conclusions: 1) IL-6 levels in bone marrow microenvironment might not be amenable to the blocking effect of the neutralizing mab; 2) other soluble factors might contribute to the pathogenesis of MM; 3) direct cell-cell interactions 11 between MM and BMSC might be of superior relevance. Based on the above presented evidence that MIP-1α
For personal use only. on September 14, 2017 . by guest www.bloodjournal.org From plays an important role in the bone resorption process typical of MM, we addressed the issue whether MIP-1α has direct effects on MM cells. Indeed, we were able to show that not only MIP-1α, but also its receptor CCR5 are expressed by MM cells and that MIP-1α triggers activation of PI3-K/AKT and MAPK pathway leading to proliferation, chemotaxis and protection against apoptosis, suggesting a major role for MIP-1α in the pathophysiology of MM. 
Transwell migration assay
MIP-1α induced cell migration was determined using a modified Boyden chamber with 8µm pore size polycarbonate membrane separating the two chambers (Costar, Cambridge, MA).
The cells were starved in media with 5% FBS for 12 h and then added onto the upper chamber membrane precoated with 10 ng/mL fibronectin. MIP-1α (0.5 to 500 ng/mL) in RPMI 1640 media with 0% FBS was added to the lower chamber. Five hours later cells, which had migrated into this chamber, were enumerated using a Coulter counter ZBII (Beckman Coulter). Fold increase in MIP-1α-specific migration was calculated by comparing the cells in the chamber following MIP-1α treatment, relative to the cells, which had spontaneously migrated in the absence of MIP-1α. 
( s e n s e ) , 5 ' -TGTCATACCAGGAAATGAG -3' (antisense). The primer pair GAPDH was used as an internal control. PCR products were separated on 1,5% agarose gel and photographed.
Statistical Analyses
Statistical significance of differences observed in MIP-1α-treated versus control cultures was determined by means of an unpaired Student's t test. P levels < 0.05 were considered to be significant. Figure 1C ), whereas we were not able to detect CCR1 and CCR9 receptors (data not shown).
MIP-1α α α α is a growth factor for human MM cells
To address the question whether MIP-1α was biologically significant in terms of tumor cell growth, we analyzed the mitogenic effect of MIP-1α on in vitro growth of MM cell lines. 15 we examined in a next step whether MIP-1α is able to prevent MM1.S cells from Dex-induced inhibition of proliferation. We confirmed that MM1.S cells are sensitive to Dex with an inhibition of proliferation from 21197±1767cpm to 5648 ±472 cpm measured by thymidine incorporation under treatment of 1µM. Even at very high concentration of MIP-1α up to 500 ng/mL, MIP-1α was not able to overcome Dex induced effects. MM1.S cells were also sensitive to Melphalan. At concentration of 10µM we observed an inhibition of proliferation from 21197 ±1767 cpm to 193±47 cpm also measured by thymidine incorporation. Concomitant treatment with MIP-1α again at very high concentrations of 500 ng/mL was not able to prevent cells from inhibition of proliferation.
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To assess whether the effects of MIP-1α are unique to myeloma we investigated MIP-1α induced proliferation in non-myeloma cells like Nalm 6, Raji, BJAB (B-cell lines) and Jurkat (T-cell line). MIP-1α did not induce proliferation in these cell lines (data not shown).
MIP-1α induces migration of MM cells
Using a modified Boyden chamber assay, we analyzed the chemotactic properties of MIP-1α on MM1.S, AS, H929, INA-6 and OPM2 cells. MIP-1α specific migration could be observed in a dose-dependent fashion in MM1.S (1.7 fold), AS (21 fold), H929 (3.6 fold), INA-6 (1.4 fold) and OPM2 (2.1 fold) compared to control as shown in Figure 3A -E.
Furthermore we wanted to investigate whether MIP-1α is able to induce migration of nonmyeloma cell lines like Nalm 6, Raji, BJAB (B-cell lines) and Jurkat (T-cell line). Migration experiments revealed that MIP-1α induced in none of these cell lines even at the highest concentration of 500 ng/mL migration (data not shown).
MIP-1 α induces AKT phosphorylation
Previously it has been shown that, besides Raf/MEK/MAPK and JAK/STAT3 pathways, which mediate survival and proliferation, AKT-dependent signaling is a major pathway in protection against apoptosis. In our study MIP- 
MIP-1α α α α stimulates AKT and its downstream targets via PI3-K activation
To further support our findings that MIP-1α induced AKT activation, we next examined whether MIP-1α also induced phosphorylation of known downstream kinases in the AKT signaling cascade. As can be seen in Figure 5A and 5B MIP-1α (100 ng/mL) led to Figure 5A , 5B).
Activation of MAPK pathway by MIP-1α
We further studied the effect of MIP-1α on MEK/MAPK and STAT signaling pathway in Recent reports showed that ERK might be activated by a PI3-K-stimulated cascade in some cell types 16, 17 and therefore it is conceivable that inhibiting PI3-K activity might prevent cytokine dependent ERK activation. Thus, we investigated the ability of PI3-K inhibitors to However, treatment with PI3-K inhibitors LY249002 had no effect on MAPK activation ( Figure 6C ). Whereas MIP-1α-induced phosphorylation of AKT in MM1.S cells could be inhibited by PI3-K inhibitors (LY249002 or wortmannin), no effect could be achieved by pretreatment with the MEK1 inhibitor PD 98059 ( Figure 6C 
Discussion
Despite significant progress in understanding the biology of MM and promising advances in the development of treatment strategies, MM remains an incurable disease leading ultimately to death of all patients. Especially, osteolytic bone lesions are still a therapeutic challenge despite the use of bisphosphonates. Recently, Rodman and colleagues could clearly demonstrate that MIP-1α is an osteoclastic factor that appears to act directly on human OCL progenitors and also acts at the later stages of OCL differentiation 18 . Antisense-mediated inhibition of MIP-1α was shown to block bone destruction in a SCID myeloma model. In addition to these effects our data show that MIP-1α also has direct effects on MM cells. Our studies suggest that MIP-1α might be an important component in the pathophysiology of MM by stimulating both MM cells and OCL responsible for the development of lytic bone lesions.
MIP-1α is a member of the CC chemokines and interacts with three types of chemokines receptors (CCR1, CCR5 and CCR9) 19 . In this study we demonstrated that MIP-1α is secreted by several MM cell lines and patient-derived AS cells in very high concentrations up to 262 ng/mL. In accordance to our data is the finding that MIP-1α levels are elevated in the bone marrow plasma of 62% patients with active myeloma 4 . Furthermore, expression of MIP-1α receptor CCR5 was observed in MM cells. Despite the constitutively high secretion of MIP-1α in MM cells shown by our own data and others 20 , we found that addition of exogenous MIP-1α at a concentration of up to 500 ng/mL increased proliferation of MM cell up to 4,7
fold and triggered migration up to 21 fold. In our experimental setting proliferation assays were performed after the cells were washed with PBS twice to remove constitutively secreted cytokines and cultured thereafter in RPMI media containing low level of FBS (2.5%).
Therefore, the initial concentration of MIP-1α in proliferation assays of the starved and washed cells is very low, whereas measurement of MIP-1α secretion of MM cells was performed at the end of 48 hours assay which could explain why MM cells show a response
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From to exogenous MIP-1α. However, it is conceivable that MIP-1α might act indirectly by inducing the expression of a so far unknown factor. Thus, we wanted to investigate whether MIP-1α triggers secretion of IL-6 or other cytokines in MM cells. Therefore, MM1.S cells were treated with 100 ng/mL MIP-1α and supernatants were collected after 48hours. Analysis revealed that MIP-1α does not increase the secretion of IL-6 and 16 other cytokines (see material and methods). In addition to that experiment we could show that MIP-1α does not induce STAT-3 phosphorylation, whereas we and others and have shown that IL-6 leads to STAT-3 21 phosphorylation. Therefore, if MIP-1α acted by IL-6, we would expect to observe phosphorylation of STAT3.
Recently Anderson et al. described that Dex is able to induce apoptosis in MM1.S cells and
IL-6 is able to prevent Dex induced apoptosis by inhibition of activation of Related Adhesion
Focal Tyrosine Kinase (RAFTK) 22, 23 . We therefore tested whether MIP-1α is able to block Notably, this induction of phosphorylation was inhibited by pre-treatment with the PI3-K inhibitor LY 294002 (50 µM, 15 min) or wortmannin (1 µM, 15 min). Since a previous study had shown that IL-6 induced ERK activation and cell proliferation was inhibited by a PI3-K inhibitor, suggesting a cross talk between MAPK and PI3-K pathway 24 , we tested whether PI3-K inhibitors were able to inhibit MIP-1α-induced ERK activation. Our results however,
clearly demonstrate in accordance with data from Tu at al. 25 , that PI3-K inhibitors have no effect on ERK, but led to a complete abrogation of the AKT phosphorylation and its down stream targets. In accordance with these findings, MEK1 inhibitor, which completely abrogates ERK activation, had no effect on AKT phosphorylation suggesting that in our cell lines MIP-1α-induced activation of ERK and AKT pathways occur separately from each other without any cross talk.
Taken together these data provide evidence that in addition to being a stimulating factor for OCL and contributing to the development of lytic bone lesions, MIP-1α also has potent direct stimulating effects on MM cells leading to a dose dependent increase of proliferation and MIP-1α-directed chemotaxis, and therefore might contribute to the homing processes of MM cells in the bone marrow microenvironment. Furthermore, MIP-1α-induced signaling involved activation of the MAPK and AKT/PKB signaling pathway in MM cells leading to increased proliferation and survival.
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